Detection of high-grade squamous intraepithelial lesions or worse by different screening methods
LU Chang, CHEN Xinyi, WANG Xiaodan, LIU Zhaohui
Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University/Beijing Maternal and Child Health Care Hospital, Beijing 100026, China
Abstract：Objective To explore the detection of high-grade squamous intraepithelial lesion or worse by thinprep cytologic test (TCT), high-risk human papillomavirus (HPV) detection and combined screening methods. Methods A total of 1721 women referred for colposcopy at gynecology clinic of Beijing Obstetrics and Gynecology Hospital from June to November of 2019 were included, and the results of TCT screening, HPV detection and cervical biopsy pathology were retrospectively analyzed. Results In the 1721 cases,the average age was 41.04±10.84 ranged from 19 to 78 years old. The detection rates of high-grade squamous intraepithelial lesions (HSIL) or worse by biopsy in AUSCUS, LSIL, ASC-H, HSIL and AGC groups were 22.6%, 25.0%, 77.3%, 90.9% and 60.0% respectively, which were significantly higher than that in NILM group (14.2%, P＜0.05). The detection rates of HSIL or worse by biopsy in HPV 16/18 positive and other HR-HPV positive groups were 22.8% and 19.0%, which were significantly higher than that in the HPV negative group (7.3%,P＜0.05). The detection rate of HSIL or worse in the positive group by TCT and HPV detection was 31.3% (205 /656), which was significantly higher than that in the control group(13.7%,146/1065; P<0.001). Conclusions TCT and high-risk HPV detection are important methods of screening HSILor worse. The patients with TCT ASC-US or worse combined with high-risk HPV should be paid more attention to improve the detection rate.
路畅, 陈心怡, 王晓丹, 刘朝晖. 不同筛查方法对宫颈高级别鳞状上皮内病变及以上的检出情况[J]. 武警医学, 2023, 34(3): 194-197.
LU Chang, CHEN Xinyi, WANG Xiaodan, LIU Zhaohui. Detection of high-grade squamous intraepithelial lesions or worse by different screening methods. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(3): 194-197.
Hu L, Bell D, Antani S, et al. An Observational study of deep learning and automated evaluation of cervical images for cancer screening[J]. J Natl Cancer Inst, 2019,111(9):923-932.
Wentzensen N, Clarke M A, Bremer R, et al. Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program[J]. JAMA Intern Med, 2019,179(7):881-888.
[7]
Lew J B, Simms K T, Smith M A, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program[J]. Lancet Public Health, 2017, 2(2): e96-e107.
[8]
Wang W, Arca E, Sinha A, et al. Cervical cancer screening guidelines and screening practices in 11 countries: a systematic literature review[J]. Prev Med Rep. 2022, 8(28):101813.
[9]
Chrysostomou A C, Stylianou D C, Constantinidou A, et al. Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing[J]. Viruses, 2018, 10(12):729.
Perkins R B, Guido R S, Castle P E, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors[J]. J Low Genit Tract Dis, 2020, 24(2):102-131.
US Preventive Services Task Force, Curry S J, Krist A H, et al. Screening for cervical cancer: US preventive services task force recommendation statement[J]. JAMA, 2018, 320(7): 674-686.
2023, Vol. 34 
